{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:47:18Z","timestamp":1793713638818,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council Singapore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer vaccines as immunotherapy for solid tumours are currently in development with promising results. We report a phase 1 study of Ad-sig-hMUC1\/ecdCD40L (NCT02140996), an adenoviral-vector vaccine encoding the tumour-associated antigen MUC1 linked to CD40 ligand, in patients with advanced adenocarcinoma. The primary objective of this study is safety and tolerability. We also study the immunome in vaccinated patients as a secondary outcome. This trial, while not designed to determine clinical efficacy, reports an exploratory endpoint of overall response rate. The study meets its pre-specified primary endpoint demonstrating safety and tolerability in a cohort of 21 patients with advanced adenocarcinomas (breast, lung and ovary). The maximal dose of the vaccine is 1 \u00d710<jats:sup>11<\/jats:sup>viral particles, with no dose limiting toxicities. All drug related adverse events are of low grades, most commonly injection site reactions in 15 (71%) patients. Using exploratory high-dimensional analyses, we find both quantitative and relational changes in the cancer immunome after vaccination. Our data highlights the utility of high-dimensional analyses in understanding and predicting effective immunotherapy, underscoring the importance of immune competency in cancer prognosis.<\/jats:p>","DOI":"10.1038\/s41467-022-33834-4","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:08:25Z","timestamp":1666984105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A phase I study of an adenoviral vector delivering a MUC1\/CD40-ligand fusion protein in patients with advanced adenocarcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Tira J.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-0550","authenticated-orcid":false,"given":"W. X. Gladys","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Who-Whong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Shan","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3089-7379","authenticated-orcid":false,"given":"Sze Huey","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Whay-Kuang","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-7652","authenticated-orcid":false,"given":"Wai Ho","family":"Shuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivashini","family":"Kaliaperumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijin","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1114","authenticated-orcid":false,"given":"Aaron C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda O. L.","family":"Seet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-1169","authenticated-orcid":false,"given":"Thaschawee","family":"Arkachaisri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-0936","authenticated-orcid":false,"given":"Valerie","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad bin Mohamed","family":"Lajam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin Z. W.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-2346","authenticated-orcid":false,"given":"Martin","family":"Wasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-6256","authenticated-orcid":false,"given":"Salvatore","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-3453","authenticated-orcid":false,"given":"Han Chong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"33834_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm0198-043","volume":"4","author":"B Agrawal","year":"1998","unstructured":"Agrawal, B., Krantz, M. J., Reddish, M. A. & Longenecker, B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4, 43\u201349 (1998).","journal-title":"Nat. Med."},{"key":"33834_CR2","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res 15, 5323\u20135337 (2009).","journal-title":"Clin. Cancer Res"},{"key":"33834_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath, S. & Mukherjee, P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 20, 332\u2013342 (2014).","journal-title":"Trends Mol. Med."},{"key":"33834_CR4","doi-asserted-by":"publisher","first-page":"110888","DOI":"10.1016\/j.biopha.2020.110888","volume":"132","author":"T Gao","year":"2020","unstructured":"Gao, T., Cen, Q. & Lei, H. A review on development of MUC1-based cancer vaccine. Biomed. Pharmacother. 132, 110888 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"33834_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc.2016.16","volume":"16","author":"SH van der Burg","year":"2016","unstructured":"van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16, 219\u2013233 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"33834_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"33834_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cgt.2012.87","volume":"20","author":"A Deisseroth","year":"2013","unstructured":"Deisseroth, A., Tang, Y., Zhang, L., Akbulut, H. & Habib, N. TAA\/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases. Cancer Gene Ther. 20, 65\u201369 (2013).","journal-title":"Cancer Gene Ther."},{"key":"33834_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/CJI.0b013e3181acea69","volume":"32","author":"C Lindqvist","year":"2009","unstructured":"Lindqvist, C., Sandin, L. C., Fransson, M. & Loskog, A. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J. Immunother. 32, 785\u2013792 (2009).","journal-title":"J. Immunother."},{"key":"33834_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/08830185.2012.692844","volume":"31","author":"G Ullenhag","year":"2012","unstructured":"Ullenhag, G. & Loskog, A. S. AdCD40L\u2013crossing the valley of death? Int Rev. Immunol. 31, 289\u2013298 (2012).","journal-title":"Int Rev. Immunol."},{"key":"33834_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2567.2003.01634.x","volume":"109","author":"TA Barr","year":"2003","unstructured":"Barr, T. A., McCormick, A. L., Carlring, J. & Heath, A. W. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology 109, 87\u201392 (2003).","journal-title":"Immunology"},{"key":"33834_CR11","doi-asserted-by":"publisher","first-page":"13407","DOI":"10.1128\/JVI.77.24.13407-13411.2003","volume":"77","author":"TC Yang","year":"2003","unstructured":"Yang, T. C., Dayball, K., Wan, Y. H. & Bramson, J. Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J. Virol. 77, 13407\u201313411 (2003).","journal-title":"J. Virol."},{"key":"33834_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","volume":"15","author":"AR Shaw","year":"2019","unstructured":"Shaw, A. R. & Suzuki, M. Immunology of adenoviral vectors in cancer therapy. Mol. Ther. Methods Clin. Dev. 15, 418\u2013429 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"33834_CR13","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.2135379100","volume":"100","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen\/CD40-ligand fusion protein to dendritic cells. Proc. Natl Acad. Sci. USA 100, 15101\u201315106 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33834_CR14","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood-2003-12-4319","volume":"104","author":"Y Tang","year":"2004","unstructured":"Tang, Y. et al. Multistep process through which adenoviral vector vaccine overcomes energy to tumor-associated antigens. Blood 104, 2704\u20132713 (2004).","journal-title":"Blood"},{"key":"33834_CR15","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.4049\/jimmunol.177.8.5697","volume":"177","author":"Y Tang","year":"2006","unstructured":"Tang, Y. et al. Vector prime\/protein boost vaccine that overcomes defects acquired during aging and cancer. J. Immunol. 177, 5697\u20135707 (2006).","journal-title":"J. Immunol."},{"key":"33834_CR16","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.4049\/jimmunol.163.11.6292","volume":"163","author":"KH Lee","year":"1999","unstructured":"Lee, K. H. et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292\u20136300 (1999).","journal-title":"J. Immunol."},{"key":"33834_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0093-7754(03)00230-6","volume":"30","author":"HK Lyerly","year":"2003","unstructured":"Lyerly, H. K. Quantitating cellular immune responses to cancer vaccines. Semin Oncol. 30, 9\u201316 (2003).","journal-title":"Semin Oncol."},{"key":"33834_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"33834_CR19","doi-asserted-by":"crossref","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).","DOI":"10.1093\/jnci\/djw261"},{"key":"33834_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","volume":"26","author":"BM Allen","year":"2020","unstructured":"Allen, B. M. et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26, 1125\u20131134 (2020).","journal-title":"Nat. Med."},{"key":"33834_CR21","doi-asserted-by":"crossref","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","DOI":"10.1038\/s41568-021-00347-z"},{"key":"33834_CR22","doi-asserted-by":"publisher","first-page":"674279","DOI":"10.3389\/fimmu.2021.674279","volume":"12","author":"JG Yeo","year":"2021","unstructured":"Yeo, J. G. et al. A virus-specific immune rheostat in the immunome of patients recovering from mild coVID-19. Front Immunol. 12, 674279 (2021).","journal-title":"Front Immunol."},{"key":"33834_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41587-020-0532-1","volume":"38","author":"JG Yeo","year":"2020","unstructured":"Yeo, J. G. et al. The extended polydimensional immunome characterization (EPIC) web-based reference and discovery tool for cytometry data. Nat. Biotechnol. 38, 679\u2013684 (2020).","journal-title":"Nat. Biotechnol."},{"key":"33834_CR24","doi-asserted-by":"crossref","unstructured":"Kumar, P. et al. Pro-inflammatory, IL-17 pathways dominate the architecture of the immunome in pediatric refractory epilepsy. JCI Insight 5, e126337 (2019).","DOI":"10.1172\/jci.insight.126337"},{"key":"33834_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"33834_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion\u2019. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"33834_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"33834_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando, M., Ito, M., Srirat, T., Kondo, T. & Yoshimura, A. Memory T cell, exhaustion, and tumor immunity. Immunol. Med 43, 1\u20139 (2020).","journal-title":"Immunol. Med"},{"key":"33834_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4049\/jimmunol.1400197","volume":"193","author":"KN Nielsen","year":"2014","unstructured":"Nielsen, K. N., Steffensen, M. A., Christensen, J. P. & Thomsen, A. R. Priming of CD8 T cells by adenoviral vectors is critically dependent on B7 and dendritic cells but only partially dependent on CD28 ligation on CD8 T cells. J. Immunol. 193, 1223\u20131232 (2014).","journal-title":"J. Immunol."},{"key":"33834_CR30","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1158\/0008-5472.CAN-16-2089","volume":"77","author":"S Nimanong","year":"2017","unstructured":"Nimanong, S. et al. CD40 signaling drives potent cellular immune responses in heterologous cancer vaccinations. Cancer Res 77, 1918\u20131926 (2017).","journal-title":"Cancer Res"},{"key":"33834_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bjc.2016.42","volume":"114","author":"A Loskog","year":"2016","unstructured":"Loskog, A. et al. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br. J. Cancer 114, 872\u2013880 (2016).","journal-title":"Br. J. Cancer"},{"key":"33834_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502 (2017).","journal-title":"Cell"},{"key":"33834_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","volume":"51","author":"CA Dutertre","year":"2019","unstructured":"Dutertre, C. A. et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 51, 573\u2013589(2019).","journal-title":"Immunity"},{"key":"33834_CR34","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/annrheumdis-2019-216059","volume":"78","author":"JY Leong","year":"2019","unstructured":"Leong, J. Y. et al. Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFalpha withdrawal. Ann. Rheum. Dis. 78, 1712\u20131721 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"33834_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","volume":"68","author":"CJ Lim","year":"2019","unstructured":"Lim, C. J. et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 68, 916\u2013927 (2019).","journal-title":"Gut"},{"key":"33834_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytom. A 87, 636\u2013645 (2015).","journal-title":"Cytom. A"},{"key":"33834_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41592-018-0308-4","volume":"16","author":"GC Linderman","year":"2019","unstructured":"Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger, S. & Kluger, Y. Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. Nat. Methods 16, 243\u2013245 (2019).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33834-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:29:11Z","timestamp":1678454951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33834-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33834"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33834-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6453"}}